drugset / Trial / NCT06846411
The EMPA-FIT Study
RandomizedParallel-groupSingle-blindTreatment
Summary
This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2025-09-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | — |
| Comparator | Metformin | Small molecule | — | — |